Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Higher revenue from the base business, increased marginal profit from the optimization of selling prices in the testing and related services business, and improved testing operations centered on the H.U. Bioness Complex contributed to higher operating income. Ordinary income declined due to the反動 from investment gains on contributions recorded in the previous fiscal year, while net income attributable to owners of the parent increased due to gains on the sale of non-current assets and investments in affiliates, among other factors.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥247,362 million (YoY +1.8%) |
| Operating profit | ¥4,780 million (YoY +81.0%) |
| Ordinary income | ¥2,834 million (YoY -40.2%) |
| Profit attributable to owners of the parent | ¥6,823 million (YoY +147.1%) |
| Net income per share | ¥121.52 |
| Operating Margin | 1.9％ |
| Equity ratio | End of the current fiscal period 51.3％ / End of previous period 49.0％ |
| Total assets | ¥267,466 million |
| Net assets | ¥137,472 million |
| Cash flows from operating activities | ¥21,565 million |
| Cash flows from investing activities | ¥11,339 million |
| Cash flows from financing activities | ¥-26,393 million |
| Cash and cash equivalents at end of period | ¥48,104 million |
| Full-year earnings forecast | Net Sales ¥256,000 million (YoY +3.5%) / Operating profit ¥9,000 million (YoY +88.3%) / Ordinary income ¥8,000 million (YoY +182.3%) / Net income ¥5,000 million (YoY -26.7%) |
| Annual Dividend Forecast | ¥125 → ¥125（0.0%） |
| Payout ratio | Fiscal year ending March 2026 102.9％ / Forecast for the fiscal year ending March 2027 138.7％ |
| Shareholder Return Policy | The Company aims for a consolidated dividend-on-equity ratio (DOE) of 6% and will implement progressive dividends. It also plans to repurchase treasury shares actively and flexibly. |
| Segment revenue | Testing and related services business ¥157,297 million (YoY +2.8%) / Clinical Testing Products ¥60,735 million (YoY +0.4%) / Healthcare-related services business ¥29,330 million (YoY -0.6%) |
| Segment profit | Testing and related services business ¥31 million / Clinical Testing Products ¥9,050 million (YoY -20.2%) / Healthcare-related services business ¥1,759 million (YoY -1.0%) |
| Regional sales | Japan ¥208,153 million / United States ¥12,190 million / Europe ¥17,816 million / Other ¥9,201 million |
| Depreciation and amortization | ¥21,139 million |
| Impairment loss | ¥118 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,290 million, Gain on sale of shares in an affiliated company ¥3,928 million, Other ¥625 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥396 million, Impairment Losses ¥118 million, Provision for compensation loss ¥400 million, Other ¥180 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Material subsequent events | At a meeting of the Board of Directors held on 14 May 2026, the Company resolved matters relating to the repurchase of treasury shares. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 57,492,322 |
| Treasury Shares at Period-End | 2,006,640 |
| Factors Behind Changes in Business Performance | Higher revenue from the base business, increased marginal profit from the optimization of selling prices in the testing and related services business, and improved testing operations centered on the H.U. Bioness Complex contributed to higher operating income. Ordinary income declined due to the反動 from investment gains on contributions recorded in the previous fiscal year, while net income attributable to owners of the parent increased due to gains on the sale of non-current assets and investments in affiliates, among other factors. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Higher revenue from the base business, increased marginal profit from the optimization of selling prices in the testing and related services business, and improved testing operations centered on the fully operational H.U. Bioness Complex contributed to higher operating income. Ordinary income declined, mainly due to the反動 from investment gains on contributions recorded in the previous fiscal year, while net income increased due to gains on the sale of non-current assets and investments in affiliates, among other factors.